Exxat Achieves ISO/IEC 42001 Certification
Strengthening Exxat's leadership in responsible AI governance to advance clinical and experiential education.
ISO/IEC 42001 establishes a globally recognized framework for managing AI systems with transparency, accountability, and ethical oversight. By aligning with this standard, Exxat reinforces its commitment to building innovative, trustworthy tools across its platforms-including Exxat Prism, Exxat Approve, and Exxat One; that enhance clinical placements, compliance tracking, and program management.
"This certification affirms Exxat's leadership in using AI responsibly to support clinical education," said
As programs face increasing enrollment and evolving accreditation demands, responsible AI offers new ways to improve efficiency without compromising equity or quality. Exxat views this certification not only as an accomplishment but as a responsibility to model how technology can strengthen education while upholding the highest ethical standards. The certification ensures these AI-driven solutions are developed under rigorous governance practices and continuous oversight, strengthening Exxat's role as a trusted partner to health sciences education.
About Exxat
Exxat is the trusted partner and recognized leader in clinical and experiential education management with their all-in-one Exxat Prism product, the Exxat One platform, and best-in-class compliance service Exxat Approve. Exxat's comprehensive ed-tech solutions deliver integrated and seamless experiences to 1400+ programs across 550+ academic institutions spanning clinical rotations, placements, curriculum mapping, compliance, evaluations, and more.
Learn more at www.exxat.com.
View original content to download multimedia:https://www.prnewswire.com/news-releases/exxat-achieves-isoiec-42001-certification-302557501.html
SOURCE Exxat
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- GT investigates: What severe ice-rock avalanches throughout history reveal about future risks
- Hire Virtue LLC Takes Human-First Recruiting Philosophy to the Masses, Recommitting to the Art of Putting People Back to Work
- Roivant to Present Topline Results from the Phase 2 PHocus Study of Mosliciguat in Patients with Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD) at the ERS Congress 2026 on T
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share